measured 705 nanomoles of copper through microneedle-treated skin in 9 hours, which is approximately 45 micrograms 3
Acosta JR, Douagi I, Andersson DP, et al
PE-22-28 Safety Considerations# PE-22-28's safety profile is less burdened by mechanism-specific concerns: TREK-1 channels are expressed throughout the body (brain, heart, vasculature, gastrointestinal tract), so systemic TREK-1 blockade could theoretically affect cardiovascular function, pain sensation, and gastrointestinal motility
The standard dose escalation begins at 2.5 mg subcutaneously once weekly for four weeks, followed by increases to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg at four-week intervals as tolerated